Halozyme Therapeutics, Inc. P/E Ratio 2009–2025
Halozyme Therapeutics, Inc. reported 26.29 of price-to-earnings ratio for fiscal 2025. That was 88.6% higher than fiscal 2024. Compared with fiscal 2020, the change was -44.0%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 26.29 | +88.6% |
| FY 2024 | 13.94 | -20.8% |
| FY 2023 | 17.60 | -55.5% |
| FY 2022 | 39.51 | +169.3% |
| FY 2021 | 14.68 | -68.7% |
| FY 2020 | 46.93 | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | 45.02 | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
Source: Halozyme Therapeutics, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open HALO 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Halozyme Therapeutics, Inc. reported 26.29 of price-to-earnings ratio for fiscal 2025. That was 88.6% higher than fiscal 2024. Compared with fiscal 2020, the change was -44.0%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Halozyme Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHalozyme Therapeutics, Inc. — frequently asked questions
What is Halozyme Therapeutics, Inc.'s price-to-earnings ratio?
Halozyme Therapeutics, Inc. (HALO) reported price-to-earnings ratio of 26.29 for fiscal year 2025, per its SEC filings.
How has Halozyme Therapeutics, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, HALO's price-to-earnings ratio declined at roughly 3.3% per year (compound annual rate), from 45.02 to 26.29.
Where does this data come from?
Figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More HALO financial history
Full HALO fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →